E-Book | February 27, 2018

Exploring The Future Of Bioprocessing Together

Source: MilliporeSigma

In the early days of biomanufacturing, companies focused primarily on approvals, with process optimization being a much lower priority. This remained the case while the prices of biologics far outstripped the costs of manufacture, but in the age of biosimilars and cost-conservative payers, companies are now re-examining cost drivers in biologics manufacture. “Today, manufacturing is a strategic imperative and an area for differentiation – an opportunity to look at new technologies that can really drive down costs,” explains Michael Phillips, Director, Next Generation Bioprocessing R&D, at MilliporeSigma. “Companies are now focusing on how to get more out of their processes, how technologies, such as single use, can help, and looking to implement in-line sensors and analytics. Increasingly, companies are also looking at the potential to connect bioprocesses.”

Experts from both biologics manufacturers and from MilliporeSigma provide their insights and perspectives on the on-going paradigm shift towards next generation bioprocessing occurring in today’s and tomorrow’s biopharma landscape.